sibutramine has been researched along with Schizophrenia in 6 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current trial investigated the effect of add-on treatment with sibutramine in schizophrenia outpatients who had gained more than 7% of weight during the course of treatment." | 9.19 | Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. ( Biedermann, F; Ebenbichler, CF; Fleischhacker, WW; Hofer, A; Kemmler, G; Lechleitner, M, 2014) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects." | 9.12 | A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007) |
| " This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder." | 9.11 | A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| " The current trial investigated the effect of add-on treatment with sibutramine in schizophrenia outpatients who had gained more than 7% of weight during the course of treatment." | 5.19 | Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. ( Biedermann, F; Ebenbichler, CF; Fleischhacker, WW; Hofer, A; Kemmler, G; Lechleitner, M, 2014) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects." | 5.12 | A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007) |
| " This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder." | 5.11 | A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| " Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)." | 3.75 | Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009) |
| "Overweight and obesity have not only a significant psychological impact but also result in an increased risk for development of numerous chronic and sometimes fatal diseases." | 2.41 | Epidemiology, morbidity, and treatment of overweight and obesity. ( Aronne, LJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biedermann, F | 1 |
| Fleischhacker, WW | 1 |
| Kemmler, G | 1 |
| Ebenbichler, CF | 1 |
| Lechleitner, M | 1 |
| Hofer, A | 1 |
| Stauffer, VL | 1 |
| Lipkovich, I | 1 |
| Hoffmann, VP | 1 |
| Heinloth, AN | 1 |
| McGregor, HS | 1 |
| Kinon, BJ | 1 |
| Henderson, DC | 2 |
| Copeland, PM | 2 |
| Daley, TB | 2 |
| Borba, CP | 2 |
| Cather, C | 2 |
| Nguyen, DD | 2 |
| Louie, PM | 1 |
| Evins, AE | 2 |
| Freudenreich, O | 2 |
| Hayden, D | 2 |
| Goff, DC | 2 |
| Fan, X | 1 |
| Zhang, H | 1 |
| Baptista, T | 1 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Aronne, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effectiveness of Cryotherapy in Slimming of the Abdomen and Saddlebags[NCT04287153] | 30 participants (Actual) | Interventional | 2017-09-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sibutramine and Schizophrenia
| Article | Year |
|---|---|
Epidemiology, morbidity, and treatment of overweight and obesity.
Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Body Height; Body Mass Index; Body Weight; | 2001 |
4 trials available for sibutramine and Schizophrenia
| Article | Year |
|---|---|
Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle | 2014 |
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Behavior Therapy; Benzodiazepines; Combined Modal | 2005 |
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
Topics: Adult; Anthropometry; Antipsychotic Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Bo | 2007 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
1 other study available for sibutramine and Schizophrenia
| Article | Year |
|---|---|
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.
Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D | 2009 |